ImmunityBio Validates Scalable NK Cell Manufacturing Yielding 5B Cells per Collection
ImmunityBio enrolled 74 subjects in its NK2022 and NK2023 Phase 1 trial, reporting zero Grade 4/5 adverse events or cytokine storms across 10 treated cancer patients. The company’s validated manufacturing pathway yields up to 5 billion M-ceNK cells per apheresis (8–10 doses available within 12 days) via its NANT Leonardo platform.
1. Manufacturing Breakthrough
ImmunityBio has validated a scalable manufacturing pathway for its autologous memory cytokine-enhanced natural killer (M-ceNK) cell platform, achieving yields of up to 5 billion highly pure NK cells from a single apheresis collection. This process produces 8–10 therapeutic doses with finished product ready within 12 days, addressing critical supply constraints in cell therapy production.
2. Phase 1 Safety Trial Highlights
The company enrolled 74 subjects across its NK2022 and NK2023 programs, completing a Phase 1 safety trial that combined M-ceNK cells with ANKTIVA®. Among 10 treated cancer patients, there were zero Grade 4 or 5 treatment-related adverse events and no cytokine storm events, underscoring a favorable safety profile.
3. Positioning for Clinical Scale
With manufacturing methods now established on the AI-driven NANT Leonardo platform, ImmunityBio is equipped to translate its cell banking infrastructure into first-in-human trials at scale. Preclinical data presented in 2026 showed statistically significant tumor volume reductions in small-cell lung cancer xenograft models when M-ceNK cells were combined with ANKTIVA®.